Cargando…

Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1

Previous studies have indicated that cytotoxic treatments may induce or not activate viral lytic cycle activation in cancer cells latently infected by Kaposi’s sarcoma-associated herpesvirus (KSHV). To investigate the molecular mechanisms responsible for such an effect, we compared two cytotoxic tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Granato, Marisa, Gilardini Montani, Maria Saveria, Angiolillo, Camilla, D’Orazi, Gabriella, Faggioni, Alberto, Cirone, Mara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356381/
https://www.ncbi.nlm.nih.gov/pubmed/30586869
http://dx.doi.org/10.3390/v11010008
_version_ 1783391525976145920
author Granato, Marisa
Gilardini Montani, Maria Saveria
Angiolillo, Camilla
D’Orazi, Gabriella
Faggioni, Alberto
Cirone, Mara
author_facet Granato, Marisa
Gilardini Montani, Maria Saveria
Angiolillo, Camilla
D’Orazi, Gabriella
Faggioni, Alberto
Cirone, Mara
author_sort Granato, Marisa
collection PubMed
description Previous studies have indicated that cytotoxic treatments may induce or not activate viral lytic cycle activation in cancer cells latently infected by Kaposi’s sarcoma-associated herpesvirus (KSHV). To investigate the molecular mechanisms responsible for such an effect, we compared two cytotoxic treatments able to induce the viral lytic cycle, named 12-O-tetradecanoylphorbol 13-acetate (TPA) (T) in combination with sodium butyrate (B) and bortezomib (BZ), with two cytotoxic treatments that did not activate this process, named metformin (MET) and quercetin (Q). Our results indicated that TB and bortezomib increased levels of oxygen reactive species (ROS) while metformin and quercetin reduced them. The finding that N-acetylcysteine (NAC), a reactive oxigen species (ROS) scavenger, counteracted K-bZIP expression induced by TB or bortezomib, confirmed that an ROS increase played a role in KSHV lytic cycle activation. Moreover, we found that TB and bortezomib up-regulated p62/Sequestosome1(p62/SQSTM1) protein, while metformin and quercetin down-regulated it. p62/SQSTM1 silencing or the inhibition of NF-E2-related factor 2 (NRF2) or Heat Shock Factor 1 (HSF1), that mediate p62/SQSTM1 transcription, also reduced KSHV lytic antigen expression induced by TB or bortezomib. Interestingly, such combination treatments further increased intracellular ROS and cytotoxicity induced by the single TB or bortezomib treatment, suggesting that NRF2, HSF1 and p62/SQSTM1 keep the ROS level under control, allowing primary effusion lymphoma (PEL) cells to continue to survive and KSHV to replicate.
format Online
Article
Text
id pubmed-6356381
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63563812019-02-05 Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1 Granato, Marisa Gilardini Montani, Maria Saveria Angiolillo, Camilla D’Orazi, Gabriella Faggioni, Alberto Cirone, Mara Viruses Article Previous studies have indicated that cytotoxic treatments may induce or not activate viral lytic cycle activation in cancer cells latently infected by Kaposi’s sarcoma-associated herpesvirus (KSHV). To investigate the molecular mechanisms responsible for such an effect, we compared two cytotoxic treatments able to induce the viral lytic cycle, named 12-O-tetradecanoylphorbol 13-acetate (TPA) (T) in combination with sodium butyrate (B) and bortezomib (BZ), with two cytotoxic treatments that did not activate this process, named metformin (MET) and quercetin (Q). Our results indicated that TB and bortezomib increased levels of oxygen reactive species (ROS) while metformin and quercetin reduced them. The finding that N-acetylcysteine (NAC), a reactive oxigen species (ROS) scavenger, counteracted K-bZIP expression induced by TB or bortezomib, confirmed that an ROS increase played a role in KSHV lytic cycle activation. Moreover, we found that TB and bortezomib up-regulated p62/Sequestosome1(p62/SQSTM1) protein, while metformin and quercetin down-regulated it. p62/SQSTM1 silencing or the inhibition of NF-E2-related factor 2 (NRF2) or Heat Shock Factor 1 (HSF1), that mediate p62/SQSTM1 transcription, also reduced KSHV lytic antigen expression induced by TB or bortezomib. Interestingly, such combination treatments further increased intracellular ROS and cytotoxicity induced by the single TB or bortezomib treatment, suggesting that NRF2, HSF1 and p62/SQSTM1 keep the ROS level under control, allowing primary effusion lymphoma (PEL) cells to continue to survive and KSHV to replicate. MDPI 2018-12-24 /pmc/articles/PMC6356381/ /pubmed/30586869 http://dx.doi.org/10.3390/v11010008 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Granato, Marisa
Gilardini Montani, Maria Saveria
Angiolillo, Camilla
D’Orazi, Gabriella
Faggioni, Alberto
Cirone, Mara
Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title_full Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title_fullStr Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title_full_unstemmed Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title_short Cytotoxic Drugs Activate KSHV Lytic Cycle in Latently Infected PEL Cells by Inducing a Moderate ROS Increase Controlled by HSF1, NRF2 and p62/SQSTM1
title_sort cytotoxic drugs activate kshv lytic cycle in latently infected pel cells by inducing a moderate ros increase controlled by hsf1, nrf2 and p62/sqstm1
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356381/
https://www.ncbi.nlm.nih.gov/pubmed/30586869
http://dx.doi.org/10.3390/v11010008
work_keys_str_mv AT granatomarisa cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1
AT gilardinimontanimariasaveria cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1
AT angiolillocamilla cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1
AT dorazigabriella cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1
AT faggionialberto cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1
AT cironemara cytotoxicdrugsactivatekshvlyticcycleinlatentlyinfectedpelcellsbyinducingamoderaterosincreasecontrolledbyhsf1nrf2andp62sqstm1